ArticleBioinformation2025
Role of immunohistochemistry in differentiating between reactive and malignant lymphoid hyperplasia - A cross-sectional study.
Article in Bioinformation, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Inflammatory-Hematological Profiles in Nasopharyngeal Carcinoma and Suspicious Adenoid Hypertrophy: An Exploratory Single-Center Study.Diagnostics (Basel, Switzerland) · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Differentiating reactive lymphoid hyperplasia from malignant lymphoma poses a diagnostic challenge due to overlapping clinical and histopathological features. Therefore, it is of interest to evaluate the utility of immunohistochemistry (IHC) in distinguishing benign reactive changes from malignant lymphoid proliferations. Lymph node biopsies from patients presenting with persistent lymphadenopathy were assessed histologically and subjected to a panel of IHC markers including CD3, CD20, CD10, BCL2 and Ki-67. The analysis revealed that IHC not only confirmed lineage specificity but also helped to identify aberrant antigen expression and proliferative indices characteristic of malignancy. Thus, we show the pivotal role of IHC in improving diagnostic accuracy, reducing misclassification and guiding appropriate therapeutic decisions in patients with lymphoid hyperplasia.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.